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Abstract
Background: The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of
induced immune mucositis and esophagitis is extremely rare.
Case presentation: We report the case of a patient with stage IV pulmonary adenocarcinoma treated for 6 months
with nivolumab who developed bilateral sterile conjunctivitis followed by oropharyngeal mucositis and esophagitis
complicated by a severe esophageal stenosis. The laryngeal margin and hypopharyngeal mucosa appeared highly
inflammatory with fibrinous deposits. Esophagogastroduodenoscopy revealed mucositis with a scar-like structure
immediately below the upper esophageal sphincter with nonulcerative mucosa and an inflammatory aspect of the
entire esophagus. No involvement of the stomach was observed. Oropharynx biopsies displayed marked lymphocytic
T cell-infiltration with several foci of monocellular necrosis in the squamous epithelium. No morphologic evidence of
adenocarcinoma and no signs of mycotic, bacterial or viral infection were noted. A blood sample revealed a discrete
increase in the erythrocyte sedimentation rate (ESR) with no eosinophilia or leukocytosis. Liver and kidney function
panel tests were normal. A thoracoabdominal CT scan reported no evidence of disease recurrence. Despite multiple
boluses of methylprednisolone and high doses of prednisone continued for several months, the patient experienced
very rapid symptomatological reappearance during three steroid tapering attempts and aggravation of his esophageal
stenosis to an aphagic stage, requiring a nasogastric tube. This long course of high-dose corticosteroid treatment was
complicated with osteoporosis-induced fractures with several spontaneous compressions of thoracolumbar vertebrae
requiring an enlarged T10 to L5 cementoplasty. Anti-IL-6 blockade therapy with tocilizumab resulted in excellent
clinical response, allowing the total resolution of the immune-related adverse events (irAEs) and leading to successful
steroid tapering.
Conclusions: Herein, we describe the first case of a patient who developed autoimmune mucositis and esophagitis
complicated by a severe refractory esophageal stenosis induced during treatment by nivolumab, which completely
resolved after personalized treatment with tocilizumab, suggesting a role of IL-6 blockade in the management of
severe steroid refractory esophageal stenosis and more broadly in refractory immune-related adverse events.
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Background
Immune checkpoint inhibitors (CPIs) have brought on-
cology into a new era by improving the overall survival
of several malignancies [1, 2]. Among them, advanced
non-small cell lung cancer (NSCLC) has become a major
indication for the use of inhibitors of programmed cell
death 1 (PD-1) and its ligand (PD-L1). The PD-1/PD-L1
axis is a crucial mediator of immune homeostasis, pre-
venting autoimmune processes in the physiological set-
ting, but also used by cancer to escape cellular immunity
[3]. By blocking this T-cell downregulator, the medical
community has been facing an entirely new spectrum of
drug-induced autoimmune diseases classically reported
as immune-related adverse events (irAEs). Although
some organ systems are predominantly involved depend-
ing on the CPIs used, any organ can be affected [4].
Lower gastrointestinal (GI) tract irAEs, such as diarrhea
and colitis, are described in up to one-third of patients
treated with inhibitors of cytotoxic lymphocyte associ-
ated protein 4 (CTLA-4), with almost 10% of events
classified as grade ≥ 3 [5]; however, these irAEs are less
frequent and severe with anti-PD1 therapies [6]. In con-
trast, upper GI tract involvement has been more fre-
quently reported with PD-1 inhibitors, although it is far
less common and still poorly characterized. Recently,
three cases of severe upper GI tract irAEs have been re-
ported, displaying either gastroesophagitis or mucositis
[7–9]. Here, we present the case of an immune mucosi-
tis and pharyngitis complicated by severe esophageal
stenosis developed during nivolumab treatment and re-
fractory to multiple corticosteroid lines but treated suc-
cessfully with personalized anti-IL-6 blockade therapy
(tocilizumab mAbs). To our knowledge, this is the first
case of nivolumab-induced esophageal stenosis subject
to personalized tocilizumab treatment reported to date.
Case report
A 67-year-old male patient diagnosed with stage IV pul-
monary adenocarcinoma was first treated with 6 cycles
of carboplatin and pemetrexed followed by a mainten-
ance regimen. Progression occurred within fourteen
month after the start of the initial treatment. Conse-
quently, second-line nivolumab was initiated at a dose of
3 mg/kg every two weeks.
After thirteen doses of nivolumab, the patient com-
plained of irritated red eyes without visual impairment.
He did not exhibit skin involvement, arthralgia or urinary
tract or digestive symptoms. The conjunctiva swab test
was negative, and no improvement was observed with
antibiotic ocular drops. The ophthalmologist’s examin-
ation revealed bilateral sterile conjunctivitis with no signs
of uveitis or retinal lesions (Fig. 1a). The patient was
treated with topical steroids with partial improvement.
A few days later, he developed fatigue and progressive
dysphagia which became severe after two months
followed by rapid 10-kg weight loss without symptoms
of associated colitis or gastritis. At that point, the main
differential diagnosis was esophageal infection, tumor
progression with gastrointestinal (GI) upper tract in-
volvement, paraneoplastic syndrome [10] or an atypical
checkpoint inhibitor-related adverse event. Of note, the
patient had no history of personal or familial auto-
immune disease, conjunctivitis or upper digestive tract
abnormality prior to nivolumab treatment. The oral
A
B
Fig. 1 Patient bilateral conjunctivitis (a) and the esophageal stenosis, 1.5 cm immediately below the upper esophageal sphincter as observed by
esophagogastroduodenoscopy (OGD) (b)
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examination initially revealed evidence for oral candidia-
sis, but treatment with a 7-day course of fluconazole did
not improve dysphagia despite the resolution of the sto-
matitis. Bacterial culture of the oropharyngeal swab was
negative, and PCR results for herpes simplex 1 and 2 in-
fection were also negative. A blood sample revealed a
discrete increase in the erythrocyte sedimentation rate
(ESR) with no eosinophilia or leukocytosis. Liver and
kidney function panel tests were normal. Thoracoab-
dominal CT scan reported no evidence of disease recur-
rence. Due to patient fatigue, a therapeutic break was
implemented for one month with the introduction of
prednisone at 30 mg per day with rapid tapering over 1
month. Although the patient initially experienced a par-
tial resolution of dysphagia, a quick recurrence of symp-
toms was noticed as the prednisone dose was tapered.
One month later, nivolumab was restarted, and the pa-
tient noticed a rapid deterioration of his dysphagia and
mucositis. The clinical situation deteriorated despite the
introduction of nystatin and steroid mouthwash, and the
patient continued to lose weight. An esophagogastro-
duodenoscopy was done, which revealed diffuse mucosi-
tis with a scar-like stenosis immediately below the upper
esophageal sphincter (Fig. 1b). Unlike the upper esopha-
gus, the lower part and the stomach were of normal
appearance.
Biopsies of the oropharynx were performed, but esopha-
geal dilatation was not performed due to the highly in-
flammatory mucosal status and patient anticoagulation.
Faced with this significant loss of weight and the impossi-
bility of an oral diet, a nasogastric tube was placed. Biop-
sies of the oropharynx displayed marked lymphocytic
inflammation and several foci of monocellular necrosis
in the squamous epithelium. Morphologic evidence of
adenocarcinoma and signs of mycotic, bacterial or
viral infection were not observed. Immunohistochemi-
cal stainings were performed in an automated stainer
(Benchmark XT; Ventana Medical Systems, Tucson,
Fig. 2 Morphological examination of oropharynx biopsies showed marked lymphocytic inflammation of the submucosa (a, original magnification × 40)
with infiltration of the epithelial layer, where scattered apoptotic cells were observed (b, original magnification × 200). Immunohistochemical staining
revealed that a minor population of lymphocytes (about 10%) was CD20 positive (c, original magnification × 100), while the majority of lymphocytic
infiltration (about 90%) was represented by CD3-positive T-cells (d, original magnification × 100). Among T-lymphocytes, about 80% were CD4
positive (e, original magnification × 100) and about 20% were CD8 positive (f, original magnification × 100)
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AZ) using 3 μm-thick sections and the following anti-
bodies: CD45 (monoclonal, clone 2B11 + PD7/26,
Dako, Glostrup, Denmark), CD19 (monoclonal, clone
BT51E, Novocastra, New Castle, UK), CD20 (mono-
clonal, clone L26, Novocastra), CD3 (monoclonal,
2GV6, Ventana), CD4 (monoclonal, SP35, Ventana),
CD8 (monoclonal, C8/144B, Dako), CD68 (monoclo-
nal, clone KP1, Dako), and PD-1 (polyclonal, R&D
System, Inc., Minneapolis, MN, USA). Immunohisto-
chemistry revealed a florid immune infiltrate, predom-
inantly with T cells (90% CD45+CD19−CD20−CD3+),
with only 10% of B cells (CD45+CD19+CD20+CD3−).
Among T cells, the majority (80%) were CD4+. Few T
cells expressed PD-1+. Rare macrophages were also
observed (Fig. 2).
Based on these results, esophageal stenosis was consid-
ered a severe irAE secondary to an important mucosal in-
flammatory infiltrate. This severe dysphagia required
enteral feeding, and nivolumab was permanently discon-
tinued after seventeen doses. The patient was treated with
125mg methylprednisolone followed by 1mg/kg oral
prednisone (total dose: 80mg). After 3 days of treatment,
the patient reported significant improvement, enabling
him to eat solid food. Prednisone was tapered by 20mg
every two weeks until reaching a daily dose of 40mg after
45 days of prednisone tapering, when he again presented
increasing symptoms of severe dysphagia.
The patient was treated a second time with 125mg
methylprednisolone for 3 days followed by 1 mg/kg oral
prednisone (total dose: 80 mg) with amelioration of
dysphagia. Three weeks later, after the reduction of
prednisone to 60mg/daily, the patient noticed a new se-
vere dysphagia deterioration, remaining aphagic. In this
context, quick endoscopic esophageal dilatation was
attempted. The laryngeal margin and hypopharyngeal
mucosa appeared highly inflamed with fibrinous deposits
on the direct laryngoscopy with no sign of salivary sta-
sis or tumor invasion. Rigid esophagoscopy revealed
erythema of the oropharynx with friable nonulcerative
mucosa and an inflammatory aspect of the entire
esophagus. Concomitant high-dose steroids at a dose
of 125 mg of methylprednisolone for 3 days followed
by 1 mg/kg prednisone again allowed transient symp-
tomatic improvement.
One month later, recurrent dysphagia did not permit
steroid tapering under 50mg/d. Furthermore, the long
course of high-dose corticosteroid treatment was com-
plicated with severe osteoporosis and several spontan-
eous compression fractures of thoracolumbar vertebrae.
Pathologic fracture due to metastases was ruled out by
bone biopsy.An enlarged T10 to L5 vertebral cemento-
plasty was carried out. One month later due to a new
episode of recurrent major dysphagia, the patient re-
ceived a new bolus of 125 mg of methylprednisolone for
3 days followed by 1 mg/kg prednisone. The serum level
of IL-6 was 3.10 pg/ml (normal range < 1.5 pg/ml), mea-
sured the same day before tocilizumab administration.
Serum levels of IL-6 were assessed by electrochemilumi-
nescence (ECL) Elecsys® IL-6 (Roche; Switzerland) ac-
cording to the manufacturer instructions.
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Fig. 3 Patient timeline chart along with key dates for clinical manifestations, specific treatments and investigations. The dose of prednisone (PDN) labelled
is the one at which the dysphagia relapse took place before the introduction of tocilizumab. PDN= prednisone, EGD = esophagogastroduodenoscopy,
Bx = Biopsy of the oropharynx
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At this point, a second line of immunosuppressive
treatment was considered. Based on the oropharynx bi-
opsy, histological analysis and the presence of a predomin-
antly T-cell infiltrate, a single intravenous administration
of the interleukin 6 receptor (IL-6R) neutralizing antibody
tocilizumab at a dose of 8mg/kg was given. This led to
rapid amelioration of the symptomatology, with successful
prednisone tapering without recurrent dysphagia. At the
present time, 3 months after the administration of toci-
lizumab, the patient has experienced no relapse of dys-
phagia. A recent rigid endoscopy confirmed complete
resolution of orolaryngopharyngeal and upper esopha-
geal inflammation (Fig. 3).
During immunosuppressive therapy we observed no
tumor progression. Eight months after discontinuing nivo-
lumab treatment, the patient remains in complete remis-
sion with no radiographic evidence of tumor relapse.
Discussion
Clinicians are progressively confronted with new types
of irAEs with increasingly pleomorphic presentation
[11]. Herein, we report the case of a patient displaying a
severe and atypical upper GI tract irAE related to nivo-
lumab immunotherapy. Oral mucositis and upper digest-
ive tract irAEs are likely underestimated in clinical trials
due to a lack of reporting given their primarily low-grade
presentations. Mild stomatitis and mucositis have been
reported in 5 to 9% of patients treated with nivolumab
or pembrolizumab [6, 12] in prospective trials. A case of
severe mucositis and esophagitis with histological docu-
mentation was reported in a patient receiving dose-esca-
lated pembrolizumab (200mg/arm every 3 weeks) in the
Keynote 012 trial [8]. The endoscopic presentation
matched ulcerative mucositis. Another patient treated
with pembrolizumab for thymoma displayed severe
cutaneo-mucositis, including esophagitis, mimicking
Steven-Johnson syndrome [9]. The third case of severe
upper GI tract irAE described in the literature involved
a patient with Hodgkin’s lymphoma presenting diffuse
esophagitis and gastritis secondary to nivolumab treat-
ment [7]. All three patients presented heterogeneous
clinical patterns, and no case involving esophageal sten-
osis has been described in the literature to date. Due to
the close anatomical proximity of these mediastinal ma-
lignancies with the upper GI tract, contiguous collateral
inflammation secondary to immune-checkpoint response
is not excluded [13]. In contrast, our patient is the only
reported patient with a tumor localized at distance from
the involved upper GI tract.
The pathophysiology of irAEs is related to the loss of
immune homeostasis, although the precise mechanism
remains incompletely characterized. Interestingly, upper
GI tract irAEs are mostly described with PD-1 inhibitors
in contrast to lower GI tract irAEs, which are more
prevalent with CTLA-4 inhibitors. These differences
highlight the probability of distinct functions of CTLA-4
and PD-1 in gut immune-homeostasis [4]. Given the in-
creased frequency and severity of ipilimumab-induced
colitis, research efforts have been more extensively fo-
cusing on these agents. CTLA-4 plays a major role in
microbiota immune-tolerance, and reciprocally its ex-
pression seems also to be influenced by the quality of
the gut flora. In contrast, further research is needed to
evaluate the role of PD-1 in the oropharynx and esopha-
geal immune homeostasis. Recent reports suggest that
the upper mucosal flora is less sensitive and thus more
stable compared with its lower digestive counterpart
[14]. The impact of chemotherapy and antibiotics on the
lower GI tract microbiota is more pronounced given its
increased bacterial load compared with the stomach and
esophagus as well as the fact that the oral microbiota is
less qualitatively sensitive to these agents [15]. These ele-
ments could explain the differences between the incidence
of upper and lower GI tract irAEs. The occurrence of dys-
biosis may stimulate the immune system, inducing a sig-
nificant increase in immune activity in patients treated
with CPIs. Interestingly, gut colonization with Klebsiella
pneumonia isolated from the salivary microbiota in pa-
tients with Crohn’s disease induces Th1-driven inflamma-
tion in inoculated germ-free mice [16]. In our patient, we
cannot exclude that the occurrence of concomitant oral
candidiasis may have participated in triggering this irAE.
The clinical course of our patient was very challenging,
with recurring severe symptomatic stenosis of the upper
esophagus upon small steroid tapers, requiring each
time boluses of methylprednisolone and increased ster-
oid doses. Several agents have been proposed for the
management of steroid-refractory or steroid-dependent
irAEs, including antibodies blocking tumor necrosis
factor alpha (TNFα) or mycophenolate mofetil, but the
two molecules have not been approved by the patient’s
insurance.
IL-6 is a principal acute inflammatory phase mediator
that plays a major role in cytotoxic T-cell differentiation
and activation and also exhibits protumor properties
[17, 18]. Thus, the use of an IL-6 blockade strategy is
particularly interesting given that it offers the advantage
of a double effect without potentially compromising the
efficacy of immunotherapy. Very interestingly, the com-
bined blockade of IL-6 and PD-1/PD-L1 axe provides
the synergistic effects not only on CD4+ Th1 response
but also on the recruitment and function of CD8+ T
cells in the tumor and its microenvironment [19, 20].
Moreover, the lack of interleukin-6 in the tumor micro-
environment augments type-1 immunity and increases
the efficacy of cancer immunotherapy [21].
After a single administration of tocilizumab, our pa-
tient showed an excellent response, allowing steroid
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tapering. Importantly, Stroud et al. proposed tocilizumab
as a second-line therapy for irAEs [22]. Clinical improve-
ment was observed in 79.4% of patients, with 52.9% of
the patients requiring only a single dose for symptomatic
response. Thereby, Stroud et al. proposed tocilizumab as
a second-line therapy for steroid-refractory irAEs.
It is important to point out that pathogenic pro-in-
flammatory IL-17A-expressing CD4+ T cells subset
(c-Kit−CD161+MDR1+ Th17 cells) have been reported to
be key effectors of autoimmune inflammation refractory
to glucocorticoids [23], which might suggest a role for
this Th17 subset in steroid refractory irAEs. Importantly,
IL-6 induces the development of Th-17 cells from naïve
CD4+ T cells [24]. Thus, the IL-6 - Th-17 pathway could
play a major role in the pathogenesis of irAEs, especially
in steroid refractory cases.
This case report supports the use of anti-IL-6 therapy
in complicated irAEs with unsatisfactory response to ste-
roids as well as the rationale to use the predominant type
of immune infiltrate on the biopsy (in this case T cells) as
a biomarker to personalize treatment in steroid-refractory
irAEs as we had just proposed in our recent therapeutic
personalized algorithm based on selective inhibition of
key inflammatory components involved in the patho-
physiological processes of irAE without compromising
cancer immunotherapy efficiency [25].
In our patient, the serum level of IL-6 was discreetly
high, which is frequently observed in cancer patients
[26]. Unfortunately, we do not have a kinetics of IL-6
serum concentrations to follow the temporal variation of
IL-6 in our patient throughout this long period of irAEs
and more particularly during corticosteroid therapy.
Between 10 and 20% of patients treated with PD-1 in-
hibitors develop unpredictable severe complications. At
this time, no risk factor has been identified to predict se-
vere irAEs, although some baseline aspects have been
noted [27]. Autoimmunity risk is associated with per-
sonal or familial history of autoimmune disease; tumor
location; and previous history of infections such as HIV,
or concomitant medications. These factors have been
proposed by Champiat et al. as predisposing factors for
the development of irAEs [28]. Few baseline biomarkers
have been identified in ipilimumab-treated melanoma
patients, such as increased circulating eosinophil count,
increased IL-17 blood levels and neutrophil infiltration
of the colon lamina propria [29]. Recently, Gowen et al.
observed a treatment-specific autoantibody signature
using a proteomic microarray approach in the baseline
serum from a subset of metastatic melanoma patients
who developed severe irAEs [30]. These potential pre-
dictive biomarkers and their specificity for CTLA-4 and
PD-1 blockade must be further examined in extended
studies to confirm previous results and potentially guide
immunotherapy management.
To the best of our knowledge, this is the first case report
to detect intraoropharyngeal T cell infiltration followed by
durable tumor response during PD-1 blockade therapy.
Further studies may reveal whether tocilizumab could be
considered also as secondary prevention, allowing to re-
sume ICIs following irAEs.
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